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Inter-~t-trypsin inhibitor is composed of three distinct protein components. These protein components stem from indepen- 
dently encoded and proteolytically processed precursor proteins. Only the structure of the protein component responsible 
for the inhibitory activity has been established so far. We now present the complete amino acid sequence of the precursor 
of the second protein component derived from cloned cDNA. The precursor molecule includes both a signal peptide 
and a propeptide sequence and seems to be further processed prior to the assembly of the inter-s-trypsin hibitor 
complex. 
Proteinase inhibitor; Inter-or-trypsin inhibitor; Propeptide; Posttranslational processing; (Human serum) 
1. INTRODUCTION 
For years it has been recognized that inter-a- 
trypsin inhibitor (ITI) is a single-chain protein 
(review [1 ]). However, ecently we could show that 
peptides obtained from purified ITI derive from 
proteins encoded on three different mRNAs [2]. 
Therefore, ITI is rather a complex of three dif- 
ferent protein components than a single-chain pro- 
tein. The inhibitor part of ITI originally perceived 
as its N-terminal portion and called H130 was 
found to be encoded on a 1.2 kb mRNA [2] iden- 
tical to that described for the urinary trypsin in- 
hibitor (UTI) [3]. The amino acid sequences of 
H130 as well as of UTI, and probably also of 
serum trypsin inhibitor (STI) [4], are identical. All 
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these molecules are formed by proteolytic process- 
ing of one and the same precursor protein with N- 
terminal a,l-microglobulin a d C-terminal Kunitz- 
type inhibitor domains. Only the inhibitor do- 
mains become part of the mature ITI complex. 
The complete amino acid sequence of the 
precursor of the second protein component of the 
ITI complex now could be derived from its cDNA 
sequence and confirmed by partial amino acid se- 
quencing of purified human ITI. 
2. MATERIALS AND METHODS 
The same human liver cDNA library from which we isolated 
a partial clone [2] was further screened with a 153 bp EcoRI- 
ClaI DNA fragment (fig.l) obtained by digestion of the cor- 
responding DNA, separation on a 4% polyacrylamide g l, dec- 
troelution with a BIOTRAP (Schleicher & Schuell) according to 
the manufacturers protocol, and labeling using the oligola- 
baling kit of Boehringer Mannheim. After a prehybridisation 
step with 3 x SSC, 3 x Denhardt, 0.1% SDS and salmon 
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GAAA~AAGT6ATATCCl.CCCCA~AcCATCT~Cl.l.TG~A~Cl.T~CAAAACTGTCCA~CAAAATGAAAAGACTCA~T~CTTTTTCATCTBCTTCTTTC 100 
-54M k R L TQF F IOF  F -43 
J , 
ITTCTBAAGiAICAGGCTTCGAAATCCCCATAAATG6ACITTCTGAATTTGTAGACTATGAAGATCTTGT~GAACTGGcCCcAGGcAAATTTcAATT~6i 200 
L S E V S G F E I P I N G L S E F V D Y E D L V E L A P G k F O l V -9 
GGcAGABAACC~A~ATATCAGAGAAGCcTTCcA~GA~AATCGGAAGAAATGATBGAAGAGGTTGATcAAGTAACTCTTTATAGCTATAAAGTCCA6TCi 300
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eA~cAT~cA~ccAAcT~c~ccA~c~Gs~c~6cAAGA~A~T~G~ATTAAG~AGA~AAc~scc~cTc~T~A~c~cA6GccA~ 500 
A~cAAAA~GcAA6Ac~scT~6c~Gs~GA~6AGcAGcBcTc~ATA~GGAAAAc~cAGAAcGGAAG~AAA~G~ccTcccA~BA~cAAA~sTBcA~c ~oo 
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TcActcAAAAc~ATTtccAtAActAcT~Ts6A6~ctcA6AGAtt6t6GTGGcA66AAAAtTt6AcccT6ctAAAtT66AtcAAAtAs~A6c6TtAtcAc 17oo 
V T Q N N F H N Y '~F .~B~.~S.~.E~. I~. .~- -A~><~. -~-~P.~~-~K><~.~-~-~.~{~.~-~-~ 492 
= 
~6C6ACTTC6~C~AACAC~CA~TTAGETT66A6ACCCT~6CCCA~AT6~AC~ACTI6CA66ATTTTCTATC~AAA6ACAA6CAT~CA6ATCCC6ATTTC 1800 
A T S A N T Q L V L E T L~<A O M D D L Q D F L S K><D K H A D P D F 525 
ACCA66AAA•T•T•••CCTATCTAACCATCAA•CAACTGCTA••T•AAC•AA••CTGG•TCCTACA•CT•CC•C•AA•A•AA•AATTA•AA•AT••ATCC 1900 
_~_R~(L,L...LAL..L..L...L._N,E.LLA.L..R~<SLAL_L.~..L.A,._K.R)~(L,.L..?~E..,I 558 
T~c~A~s~iTc~ABAccAccAcA~G~BAc~c~GcTBAcctc~cT~a~BATcsn~AAca~c~BBBAT~A~cacAr~c~BBc~A~BccccAccscA 2000 
L O M S L D H H I V T P L T S L V I E N E A- 6 D E R~<M L A D A P P 0 592 
66ATCCCTCCT6CTsCT•A••66CCCT6TATTACG••A6CAAA•T•6TTCCA•ATTCCACC•C6T•TT•6•CCAATCCTTCACCAAC6CCC•T•AT•TCC 2100 
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AT~cT66cAcAAB6A~CTCA6~T6CTAaAa~CcA~ECCACCc~CACATaT6ATaA~AaTT~AAAATaACccACATTTCAT~ATTTATCTAC~AR~cc 2200 
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AAAA6AACA~TTGT~T~AATATT~ACT~A6AACC~6AAAAA~TCAACC~a~TT~TBACC~A~AAT~A~AA~TA~TCAAC~6TCA6CTT~TT66 2300 
Q K N I (~)F  N I D S E P G K I L N L V S D P E S G I V V N G Q L V B 692 
V S L T Q N L E K S S T W F L T Q N Q E L 684 
TGCCAAGAABCCCAACAATGGAAAACTAAGCACCTATTTI'GGAAAACTGGGATTT A TTCCAAAGTGAAGACATAAAAATAGAAATCAGCACTGAGACC 2400 
A K K P N N G K L S T Y F G K L G F Y F O S E D I K I E I S T E T 725 
ATCACCCT~A~CCAT~Tl~CTA~CACATTCTCCTTGTCCTGGTCCGACAC~GCTCAAGTCACGAATCAGAG~Gl.GCA~ATCTCA~T~AA~AAA~AAA~A~ 2500 
I T L S H G S S T F S L S W S D T A Q V T N 0 R V 0 I S V K K E K 758 
T~TAACTATCA~CCT~GATAAA~A6AT6TCCTTTTCT6TTTTACTTCATC~T6TTT6~AA6AA6CAT~Z6TCAAT6TT~ACTTT~T666AATCTACAT 2600 
V V T I T L D K E M S F S V L L H R V W K K H P V N V D F L G I Y I 792 
ACCCCCTACAAACAA6TTCT•ACCTAAA6CCCAC66ACTAATA66CCA6TTCATGCA66AACCAAA6ATACACATCTTCAAT•A•A6ACCA66AAA6•AC 2700 
P P T N K F S P k A H G L I G O F M Q E P K I H I F N E R P B K D 825 
e 
CCT•A•AA•CCA•A••CCA•CAT•GAA•T•AA•G••CA•AA•CTGATCATCACCA••••CTTACAGAAA•A[TACAGAAC••AT•TA•T•TTT••AAC•• 2800 
P E K P E A S M E V K B O K L I I T R B L O K D Y R T D L V F @ T 858 
i i 
ACGTTACCT~CT~TTTGTGCACAACA~T~AAAA~ATT~ATT~AC~CATTACAA~ATTACTTCBT~CCTCA~CTCTACA~CTTTCTCAAAC~CC 2900 
D V T@W F V H N 5 B K B F i D G H Y K D Y F V P Q L Y S F L K R P 892 
TTAAA66TTTATA6TTT~6AAATTATATATATTAATATACATCTTTCC~T6TCA~TTTT~C~BATATTCTT~GTTT~AATAATTAAAAT~AACCAGA 3000 
i 
TATCAB••T••TTAATTAAAAT•AACCA•ATATCA•••T•GTTTATAAA•CCT•TAAA•A•A•CTAA•AAAATAAA•ATTTTACAAAT•p•• y (A) 3089 
Fig. 1. cDNA-derived complete amino acid sequence of the precursor of the second protein component of ITI. Partial]}, or completely 
amino acid sequenced peptides obtained by cleavage of purified ITI with either trypsin, chymotrypsin, Staphylococcus aureus V8 pro- 
teinase or CNBr are underlined and shown in brackets < >.  * marks a deleted T in one of the clones. The resultant alternative reading 
frame is shown in the line below. N + : Asn-N-acetylgaiactosamine. 4-Carboxyglutamic acid residues are underlined by a thick bar. 
Signal peptide and propeptide cleavage sites as well as potential C-terminal processing sites are indicated by triangles. 
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sperm DNA at a concentration f 200/~g/ml for 2 h at 68°C 
plaque hybridisation was performed in the same buffer over- 
night at a temperature gradient from 68 to 37°C. The applied 
radioactivity was 1 X 10 4 cpm/ml. The nitrocellulose filters 
(BA85, Schleicher & Schuell) were washed at room temperature 
twice with 3 x SSC, 0.1% SDS, twice with 1 x SSC, 0.1% 
SDS and once with 0.1 x SSC, 0.1% SDS [1 x SSC: 0.15 M 
NaCl/0.015 M sodium citrate (pH 7); 1 x Denhardt: bovine 
serum albumin, ficoll, and polyvinylpyrrolidone, 0.020/0 each]. 
Autoradiography was performed with Kodak XAR film at 
-70°C using DuPont amplifier screens overnight. Positive 
plaques were rescreened once. 
Sequence data were collected and analysed using the 
MicroGenie R Sequence Analysis Program [5], version 4.0, and 
GenBank R and NBRF sequence databanks, releases 10/87. 
Other materials and methods were as described [2]. 
3. RESULTS 
eDNA sequencing of the full-length eDNA clone 
coding for ~rl-microglobulin and the Kunitz in- 
hibitor domains revealed that the 5'-untranslated 
region of the eDNA is 15 bp longer than that 
reported in the literature [3]. The eDNA starts with 
the sequence GGCTCTTCTC GTrGC followed 
by the published sequence and therefore has a 
length of 1228 bp preceding the poly(A) tail. 
The eDNA coding for the second protein com- 
ponent of the inter~-trypsin inhibitor complex 
could be derived from two overlapping clones and 
comprises 3089 bp and a poly(A) tract. The eDNA 
sequence (fig.l) deviates in three positions (857, 
864, 917) from the partial sequence previously 
reported (fig. 1 in [2], positions 1, 8 and 62). These 
deviations were recognized as part of the cloning 
linker sequence, as a correctly determined but ar- 
tificially surplus nucleotide, and an error in typing, 
respectively. 
After a 5'-non-coding region of 63 bp a large 
open reading frame of 2838 bp encodes a protein 
of  946 amino acid residues with a calculated mole- 
cular mass of 106 447 Da. This is in relatively good 
agreement with the observed value of about 95 
kDa obtained after in vitro translation of baboon 
liver mRNA and immunodetection f ITI precur- 
sor proteins [6]. 
There is no striking homology to any other pro- 
tein in the database we used. The significance of 
some short and distant relationships of parts of the 
molecule to other proteins or parts thereof is dif- 
ficult to judge without further information. 
4. DISCUSSION 
Eukaryotic signal peptides vary considerably 
with respect to length and sequence. The main 
common denominator appears to be a more basic 
N-terminal region and a central clustering of 
hydrophobic amino acids followed by a more polar 
C-terminal region. Analysis of this common pat- 
tern allowed the deduction of some rules for the 
prediction of the cleavage site between a signal 
peptide and the exported protein [7]. According to 
these rules and the prediction of a characteristic fl- 
turn at this position in the precursor of the second 
ITI component cleavage after the glycine residue 
- 37 is most likely (fig.2). The signal peptide con- 
tains an unusually high content of phenylaianine 
rather than leucine residues. 
After CNBr cleavage of purified ITI, isolation 
and amino acid sequencing of  the peptides, the N- 
terminus of the mature second ITI component is 
clearly identified by the absence of a methionine 
residue in the precursor molecule upstream of the 
peptide S-L-P-G-E-S-E-E-M (fig.2). Therefore, 
the amino acid sequence from positions -36  to 
- 1 must represent a propeptide. Processing just 
behind the arginine residue in position - 1 would 
be plausible. Actually, ~-turns are predicted at this 
site (fig.2). 
Obviously, further proteolytic processing oc- 
curs. Peptides, enzymatically derived from isolated 
ITI, are densely distributed over only part of the 
coding region but do not cover the large C- 
terminal stretch of the precursor protein. Although 
the C-terminal amino acid of the mature protein 
could not yet be determined with certainty, of the 
potential mono- or dibasic cleavage sites [8] the 
arginyl bond at position 644 seems to be a con- 
ceivable candidate for processing by the same 
trypsin-like nzyme which cleaves off the propep- 
tide. The mature protein would thus have 4 cys- 
teine residues arranged in pairs. 
One of four clones covering the DNA sequence 
region around nucleotide position 2212 (asterisk in 
fig. 1) clearly has a deletion of a T in this position 
as verified by sequencing in both strands. This 
leads to an interruption of the altered open reading 
frame shortly after this event (second reading 
frame in fig. 1, positions 663-684). The existence of 
such a precursor protein remains to be proven. C- 
terminal processing would be possible at the same 
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Fig.2. Signal peptide, propcptide and N-terminal protein sequence of the mature second ITI protein, including its secondary structure 
plot [9] and hydropathy plot [10]. The boxes, zig-zags, flat lines and arrows represent regions of a-helices, B-strands, random coils 
and B-turns, respectively. 
amino acid residue thus producing the same 
mature protein as discussed above. 
The proteolytically trimmed nude second pro- 
tein of the ITI complex would have a calculated 
molecular mass of 66 323 Da. Like the first protein 
component of ITI which represents the Kunitz- 
type inhibitor domains the second protein compo- 
nent is also glycosylated. There are three putative 
glycosylation sites (N-X-T/S) at amino acid 
residues 42, 64 and 617. Only two (64, 617) were 
found to be derivatized (fig. 1). In experiments o
separate ITI into its components one can observe 
values of 78 and 85 kDa for those parts of the ITI 
complex that do not represent the Kunitz-type in- 
hibitor domains [11]. This is in accordance with 
the present data. 
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